Invitrogen introduces new in vivo RNAi delivery reagent

Using proprietary technology, the Invivofectamine delivery reagent allows researchers to directly study the effects of short interference ribonucleic acid (siRNA) inside a living organism for a variety of applications, including the drug discovery process.

According to the company, Invivofectamine delivery reagent can be injected in small volumes and without high pressure, minimizing the potential of inconsistent results. It also provides extra stability to siRNA so the siRNA will arrive intact and ready to perform the selected knockdown. The reagent is non-viral and has minimal toxicity. Overall, these characteristics will enable researchers to more effectively optimize their siRNA experiments in vivo, the company said.

Charles Piazza, vice president and general manager of Invitrogen’s molecular biology, said: “The Invivofectamine reagent is a major breakthrough for the development of RNAi applications in animals that could lead to the rapid discovery of new therapeutic solutions for cancer and metabolic diseases.

“Invivofectamine reagent gives customers the ability to perform in vivo RNAi experiments that have so far been difficult to perform due to the lack of an effective and easy-to-use delivery reagent.”